Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) has reached a significant milestone as its drug candidate CMND-100 arrives in the United States, preparing for its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) treatment.
The clinical trial will evaluate CMND-100, a proprietary MEAI-based oral drug candidate, for safety and efficacy in reducing alcohol consumption. The study will be conducted at prestigious institutions including Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine, and IMCA in Ramat Gan, Israel.
The company is targeting a significant market opportunity, as AUD affects over 28 million adults in the U.S., with an estimated global market potential of $35 billion. CMND-100 aims to reduce alcohol consumption and cravings through a novel mechanism of action.
Positive
- FDA approval received for Phase I/IIa clinical trial
- Partnerships with prestigious research institutions (Yale and Johns Hopkins)
- Large market opportunity: $35B global AUD treatment market
- Significant addressable patient population: 28M+ adults with AUD in U.S.
Negative
- Early-stage clinical trial - no proven efficacy yet
- No revenue generation at current stage
News Market Reaction – CMND
On the day this news was published, CMND declined 4.27%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.
CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of action. The drug’s arrival in the U.S. keeps Clearmind on track to launch its first-in-human clinical trial.
"This milestone brings us closer to demonstrating CMND-100’s potential as a transformative treatment for Alcohol Use Disorder," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “With an estimated
Clearmind’s Phase I/IIa clinical trial, approved by the U.S. Food and Drug Administration (FDA), will assess CMND-100’s safety and efficacy in reducing alcohol consumption. The study will be conducted at two of the leading research institutions in the United States, Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of Medicine. The Israeli trial will be conducted at IMCA (Israel Medical Center for Addiction), located in Ramat Gan, Israel.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses acceptance of psychedelic therapies continuing to grow within the medical community and how building a robust intellectual property portfolio establishes Clearmind as a pioneer and leader in the next generation of treatments for binge behavior. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the market potential for Clearmind Medicine's CMND-100 drug candidate?
Where will Clearmind Medicine (CMND) conduct its Phase I/IIa clinical trials for CMND-100?
What is the purpose of Clearmind Medicine's CMND-100 drug candidate?
What stage is Clearmind Medicine's CMND-100 clinical trial currently in?
